Clinics don't fail because of bad outcomes.

They fail because the systems around them couldn't hold.

When a practice sources peptides labeled "research use only," the risk isn't just contamination or inconsistent dosing. It's what happens when something goes wrong and there's no paper trail, no Certificate of Analysis, no FDA-registered supplier.

503A compounding exists for a reason. Prescriptions. State oversight. USP standards. Sterility testing. Traceability.

Research-grade peptides have none of that.

No cleanroom. No recall system. No legal recourse.

The pricing looks attractive until you realize what you're trading: the ability to defend your practice if a patient files a complaint, if a board investigates, if a supplier disappears.

And that's before we talk about brand.

Patients increasingly understand the difference between pharmaceutical-grade and gray-market. They're reading labels. They're asking questions. When they discover their "wellness clinic" was sourcing from unregulated labs, they don't see cost savings.

They see corner-cutting.

503A isn't just compliance. It's infrastructure.

The practices building long-term brands aren't optimizing for margin on the buy side. They're building systems that survive scrutiny.

The FDA found rodents, insects, and a live spider in a compounding pharmacy owned by Hims & Hers. The same facility that was producing injectable semaglutide for human use.

A dead cricket was found in the incubator room. The room where they store vials that get injected into people's bodies.

This isn't a minor paperwork violation. This is a fundamental failure of manufacturing standards for drugs that go directly into human tissue.

And it gets worse.

A patient who took their compounded semaglutide ended up hospitalized for three nights with severe gastrointestinal complications. The company never filed the required adverse event report. The FDA only found out during the inspection.

When a patient ends up in the hospital from your product and you don't report it, that's not an oversight. That's a choice.

Hims' public response was predictable. "Patient safety and regulatory compliance are foundational to how we operate." The same boilerplate language every company uses when they get caught. Meanwhile, they're already launching a compounded oral semaglutide that has the FDA threatening swift action and the Department of Justice opening an investigation.

Here's what bothers me most about this story.

Compounding pharmacies serve a legitimate and important role in medicine. They allow physicians to customize medications for patients who need specific formulations, dosages, or combinations that mass-manufactured drugs don't provide. I use compounding pharmacies in my practice for peptides and regenerative therapies. Done right, with proper quality controls and rigorous standards, compounding is a valuable tool.

But "done right" is the operative phrase.

What Hims built isn't medicine. It's a direct-to-consumer funnel designed to move as much product as possible with minimal friction. No real physician relationship. No comprehensive evaluation. No ongoing monitoring. Just an online questionnaire, a quick telehealth rubber stamp, and a shipment to your door.

That model works fine for selling shampoo. It's dangerous when you're injecting peptides into human beings.

The semaglutide gold rush has made this worse. Patients are desperate for access. Novo Nordisk can't meet demand and charges prices that put the drug out of reach for most people. Into that gap stepped compounding pharmacies and telehealth platforms promising the same results at a fraction of the cost.

Some of those pharmacies maintain rigorous standards. Some of them operate exactly as they should.

And some of them have dead crickets in their incubator rooms.

The problem is that patients have no way to know the difference. They see a slick website, a celebrity endorsement, a price that seems reasonable, and they assume someone is making sure this is safe. They assume the FDA is watching. They assume the company wouldn't sell them something manufactured in a facility with pest infestations.

Those assumptions are wrong.

The regulatory infrastructure is not built to handle the explosion of telehealth prescribing and direct-to-consumer compounding. The FDA is playing catch-up. State pharmacy boards are overwhelmed. By the time violations surface, thousands of patients have already injected products from compromised facilities.

This is what happens when healthcare gets disrupted by people who see patients as customers and medicine as e-commerce.

I'm not against innovation. I'm not against making medications more accessible. I use peptides in my practice because I've seen what they can do for patients when administered properly, with real oversight, as part of a comprehensive treatment plan.

But accessibility without accountability isn't progress. It's recklessness with good marketing.

The Hims story isn't an anomaly. It's a warning about what happens when the pressure to scale overwhelms the obligation to do things right. When growth metrics matter more than manufacturing standards. When adverse events go unreported because reporting them might slow down the machine.

Patients deserve better than this.

They deserve to know that the medications going into their bodies were made in facilities that meet basic sanitary standards. They deserve physicians who actually evaluate them, not algorithms that process them. They deserve companies that report complications honestly instead of burying them.

If your healthcare company has rodents in the manufacturing facility and doesn't report hospitalizations, you're not disrupting medicine.

You're just cutting corners and hoping no one notices.

I've spent the past decade building and scaling operations across clinics, telehealth platforms, and compounding pharmacies. I've seen practices succeed at 20 patients per month and break at 200. I've watched regulatory shifts reorganize entire markets overnight. I've built the infrastructure that determines whether modern therapies scale or stall.

This newsletter is about understanding how the system actually functions, where friction hides, and why some approaches compound over time while others don't.

If you're building, running, or participating in modern health in any real way, this layer matters more than most people realize.